Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals to Present at the Banc of America Securities Health Care Conference 2005
Momenta Pharmaceuticals to Present at the Banc of America Securities Health Care Conference 2005 CAMBRIDGE, Mass., May 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2005
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2005 CAMBRIDGE, Mass., May 10 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced its
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged Conference
Momenta Pharmaceuticals to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged Conference CAMBRIDGE, Mass., April 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at the Second Annual Rodman & Renshaw Techvest Global Healthcare Conference
Momenta Pharmaceuticals to Present at the Second Annual Rodman & Renshaw Techvest Global Healthcare Conference CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at the Deutsche Bank Securities 30th Annual Health Care Conference
Momenta Pharmaceuticals to Present at the Deutsche Bank Securities 30th Annual Health Care Conference CAMBRIDGE, Mass., April 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date for 2005 Annual Meeting of Stockholders
Momenta Pharmaceuticals Announces Date for 2005 Annual Meeting of Stockholders CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced that it
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2005 Financial Results
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2005 Financial Results CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Executive Promotions
Momenta Pharmaceuticals Announces Executive Promotions CAMBRIDGE, Mass., April 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced senior management promotions.
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Momenta Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference CAMBRIDGE, Mass., March 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Changes to Board of Directors
Momenta Pharmaceuticals Announces Changes to Board of Directors CAMBRIDGE, Mass., March 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that
View HTML